“Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall” (2026) Sriwijaya Journal of Ophthalmology, 8(2), pp. 478–485. doi:10.37275/sjo.v8i2.137.